Table 2.

Results of model estimating change in % flow-mediated dilation, cutaneous vascular conductance in response to acetylcholine and to sodium nitroprusside, and mean arterial pressure at 3 and 6 months follow-up: all participants

Variables	Group/follow-up	B-coeff	Exp (B)	95% CI		p value
				Lower	Upper
%FMD
Group	NRT over nicotine-containing e-cigarettes	0.43	1.56	− 0.64	1.50	0.43
	Nicotine-free e-cigarettes over nicotine-containing e-cigarettes	− 0.59	0.56	− 1.76	0.59	0.33
Follow-up	3 m over baseline	3.33	27.90	2.61	4.05	0.001
	6 m over baseline	2.69	14.67	2.02	3.35	0.001
Gender	Male over female	− 1.32	0.27	− 2.24	− 0.40	0.005
Age		− 0.02	0.98	− 0.05	0.01	0.23
Intercept		9.89		8.29	11.5	0.001
Peak CVC for Ach
Group	NRT over nicotine-containing e-cigarettes	− 0.03	0.97	− 0.26	0.20	0.80
	Nicotine-free e-cigarettes over nicotine-containing e-cigarettes	− 0.01	0.99	− 0.25	0.23	0.93
Follow-up	3 m over baseline	0.20	1.27	0.01	0.40	0.04
	6 m over baseline	0.27	1.31	0.09	0.45	0.004
Gender	Male over female	− 0.02	0.99	− 0.21	0.18	0.88
Age		− 0.01	0.99	0.994	0.01	0.17
Intercept		1.79		1.36	2.23	0.001
Peak CVC for SNP
Group	NRT over nicotine-containing e-cigarettes	− 0.03	0.98	− 0.26	0.29	0.83
	Nicotine-free e-cigarettes over nicotine-containing e-cigarettes	− 0.14	0.87	− 0.37	0.09	0.23
Follow-up	3 m over baseline	0.26	1.52	0.10	0.42	0.001
	6 m over baseline	0.28	1.57	0.11	0.45	0.002
Gender	Male over female	− 0.07	0.93	− 0.26	0.12	0.48
Age		− 0.01	1.00	0.995	0.01	0.16
Intercept		1.63		1.23	2.03	0.001
MAP
Group	NRT over nicotine-containing e-cigarettes	− 1.51	0.22	− 4.24	1.23	0.28
	Nicotine-free e-cigarettes over Nicotine-containing e-cigarettes	0.28	1.33	− 2.88	3.44	0.861
Follow-up	3 m over baseline	− 1.74	0.18	− 2.57	− 0.91	0.001
	6 m over baseline	− 1.41	0.25	− 2.31	− 0.51	0.002
Gender	Male over female	4.33	75.55	1.86	6.79	0.001
Age		0.23	1.26	1.15	1.39	0.001
Intercept		9.54		7.92	11.17	0.001

ACh, acetylcholine; CVC, peak cutaneous vascular conductance; %FMD, percentage change in flow-mediated dilation; MAP, mean arterial pressure; SNP, sodium nitroprusside